ObsEva, which is developing treatments for pregnancy-related conditions, received the funding from investors including pharmaceutical companies Merck Serono and Novo.

ObsEva, a Switzerland-based developer of drugs to treat serious pregnancy-related conditions, closed a CHF60m ($59m) series B round yesterday featuring corporate venturing subsidiaries of pharmaceutical firms Merck Serono and Novo.

The corporate units, Novo Ventures and MS Ventures, invested alongside HBM Healthcare Investments, New Enterprise Associates, OrbiMed, Rock Springs Capital, Sofinnova Ventures and Sofinnova Partners.

ObsEva is developing drug candidates that include an oral oxytocin antagonist in phase 2 studies for preterm labour and assisted reproductive technology, while another preterm…